KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $25.00 Average PT from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have received an average rating of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $23.80.

A number of research analysts have issued reports on the stock. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $30.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 target price for the company. Bank of America assumed coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective for the company. Finally, Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,627 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $9.75, for a total value of $74,363.25. Following the sale, the chief executive officer now owns 274,596 shares in the company, valued at $2,677,311. This represents a 2.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the transaction, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. This represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,291 shares of company stock valued at $304,086. 10.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. SG Americas Securities LLC grew its position in KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 1,319 shares in the last quarter. HighVista Strategies LLC grew its holdings in shares of KalVista Pharmaceuticals by 4.5% during the 3rd quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock worth $386,000 after purchasing an additional 1,432 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock worth $262,000 after purchasing an additional 1,670 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after purchasing an additional 2,043 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after purchasing an additional 3,314 shares in the last quarter.

KalVista Pharmaceuticals Trading Up 5.7 %

Shares of KalVista Pharmaceuticals stock opened at $9.75 on Friday. The stock has a market capitalization of $481.85 million, a price-to-earnings ratio of -2.68 and a beta of 0.85. The firm’s 50-day moving average price is $8.81 and its two-hundred day moving average price is $10.77. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. As a group, equities research analysts predict that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).